Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FILIP1LΔC103
- Development stage
- Preclinical
- Modality
- Gene Therapies
- Administration
- Intraperitoneal
01
Overview
FILIP1LΔC103 is a COOH-terminal truncation mutant (amino acids 1–790) of Filamin A Interacting Protein 1-Like (FILIP1L), used experimentally as a gene therapy for cancer. Delivered via nanogel-encapsulated recombinant plasmid, FILIP1LΔC103 inhibits tumor cell proliferation and angiogenesis, and induces apoptosis in ovarian cancer models. In preclinical studies, it has demonstrated enhanced anti-tumor effects, especially when combined with cisplatin, and acts primarily by suppressing tumor growth and blocking new vessel formation (anti-angiogenic effect)[1].
- Other names
- FILIP1LDC103FILIP-1LDC103FILIP 1LDC103
02
Targets
FILIP1L (Filamin A-interacting protein 1-like)
Beyond the preview
Go deeper on FILIP1LΔC103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FILIP1LΔC103.